[{"id":"ea7e7be5-dd5d-4509-9884-da4eb277aa63","acronym":"P+R-ICE","url":"https://clinicaltrials.gov/study/NCT05221645","created_at":"2022-02-05T18:29:06.759Z","updated_at":"2025-02-25T16:17:16.628Z","phase":"Phase 2","brief_title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05221645 - P+R-ICE","lead_sponsor":"University of Southampton","biomarkers":" CD20","pipe":" | ","alterations":" CD34 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • carmustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/27/2022","start_date":" 06/27/2022","primary_txt":" Primary completion: 05/30/2026","primary_completion_date":" 05/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-05"},{"id":"d4a4b614-9437-441a-b677-6d9779d8b5f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01780662","created_at":"2021-01-18T07:51:01.377Z","updated_at":"2024-07-02T16:36:22.313Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01780662","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Adcetris (brentuximab vedotin) • liposomal gemcitabine (FF-10832)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 01/31/2013","start_date":" 01/31/2013","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2021-10-28"},{"id":"26dcd2fa-ec50-459b-9b24-a5633f4a1586","acronym":"","url":"https://clinicaltrials.gov/study/NCT02703779","created_at":"2021-01-18T13:12:05.048Z","updated_at":"2024-07-02T16:36:28.932Z","phase":"Phase 2","brief_title":"Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)","source_id_and_acronym":"NCT02703779","lead_sponsor":"Siddhartha Ganguly","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/04/2019","primary_completion_date":" 10/04/2019","study_txt":" Completion: 04/08/2020","study_completion_date":" 04/08/2020","last_update_posted":"2021-06-18"},{"id":"2d0e25a1-48b8-42d8-ab0d-c9af2f7ab8c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01474681","created_at":"2021-01-18T06:09:06.435Z","updated_at":"2024-07-02T16:36:36.706Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of HSC835 in Patients With Hematological Malignancies","source_id_and_acronym":"NCT01474681","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spanlecortemlocel (MGTA-456)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 01/09/2012","start_date":" 01/09/2012","primary_txt":" Primary completion: 10/03/2016","primary_completion_date":" 10/03/2016","study_txt":" Completion: 10/03/2016","study_completion_date":" 10/03/2016","last_update_posted":"2020-12-30"},{"id":"3ec817c8-c912-443a-9a37-cdb4b0145ea1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01605032","created_at":"2021-01-18T06:51:53.103Z","updated_at":"2024-07-02T16:36:41.811Z","phase":"Phase 2","brief_title":"Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma","source_id_and_acronym":"NCT01605032","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • melphalan • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2020-08-20"},{"id":"1e974883-8eac-41fa-b002-5587e91aec89","acronym":"","url":"https://clinicaltrials.gov/study/NCT00004853","created_at":"2021-01-17T22:56:18.874Z","updated_at":"2024-07-02T16:36:53.833Z","phase":"Phase 1","brief_title":"Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy","source_id_and_acronym":"NCT00004853","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/03/2000","start_date":" 03/03/2000","primary_txt":" Primary completion: 05/20/2009","primary_completion_date":" 05/20/2009","study_txt":" Completion: 05/20/2009","study_completion_date":" 05/20/2009","last_update_posted":"2019-11-12"},{"id":"eb20b8a5-3ed9-42db-92ae-f5d814060799","acronym":"Interfant06","url":"https://clinicaltrials.gov/study/NCT00550992","created_at":"2021-01-18T02:00:23.012Z","updated_at":"2024-07-02T16:36:57.586Z","phase":"","brief_title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","source_id_and_acronym":"NCT00550992 - Interfant06","lead_sponsor":"Dutch Childhood Oncology Group","biomarkers":" KMT2A • CD34","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • CD34 positive","tags":["KMT2A • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • vincristine • prednisone • daunorubicin • mitoxantrone • leucovorin calcium • melphalan • Oncaspar liquid (pegaspargase) • mercaptopurine • busulfan • thioguanine • cyclosporine • prednisolone"],"overall_status":"Unknown status","enrollment":" Enrollment 445","initiation":"Initiation: 01/01/2006","start_date":" 01/01/2006","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":"","study_completion_date":"","last_update_posted":"2019-07-30"},{"id":"4878c545-1abc-40e1-850b-d27be0d5f377","acronym":"ACT-1","url":"https://clinicaltrials.gov/study/NCT00646854","created_at":"2021-01-18T02:24:24.264Z","updated_at":"2024-07-02T16:37:02.320Z","phase":"Phase 3","brief_title":"Alemtuzumab and CHOP in T-cell Lymphoma","source_id_and_acronym":"NCT00646854 - ACT-1","lead_sponsor":"Aarhus University Hospital","biomarkers":" CD34 • CD52","pipe":" | ","alterations":" CD34 positive • CD52 expression","tags":["CD34 • CD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive • CD52 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Campath (alemtuzumab) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2019-03-01"},{"id":"a908779d-6164-43fb-b7ad-52d8a10dee8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00238433","created_at":"2021-01-18T00:48:25.597Z","updated_at":"2024-07-02T16:37:17.509Z","phase":"Phase 2","brief_title":"Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00238433","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • thiotepa • busulfan • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-09-27"},{"id":"abb4725d-8f37-4d84-8422-ef08642b88ee","acronym":"NordCML006","url":"https://clinicaltrials.gov/study/NCT00852566","created_at":"2021-01-18T03:14:43.961Z","updated_at":"2024-07-02T16:37:17.594Z","phase":"Phase 2","brief_title":"Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia","source_id_and_acronym":"NCT00852566 - NordCML006","lead_sponsor":"Norwegian University of Science and Technology","biomarkers":" ABL1 • BCR • CD34","pipe":" | ","alterations":" CD34 positive","tags":["ABL1 • BCR • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 02/01/2011","primary_completion_date":" 02/01/2011","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-09-25"}]